Spots Global Cancer Trial Database for Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
Official Title: Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma
Study ID: NCT01266707
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A\*2402 restricted patients with advanced hepatocellular carcinoma.
Detailed Description: It has been required to develop new treatment modalities for patients with advanced heptatocellular carcinoma. Immunotherapy is one of the encouraging modalities for patients. We have to assess its toxicities, clinical response and immune responsiveness.
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fukushima Medical University Hospital, Fukushima, , Japan
Contact Details
Name: Mitsukazu Gotoh, PhD & MD
Affiliation: Fukushima Medical University, Department of Regeneration Surgery
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
